Tandem Diabetes Care (NASDAQ:TNDM) Shares Acquired Rep. Josh Gottheimer

Key Points

• Representative Josh Gottheimer acquired shares of Tandem Diabetes Care (NASDAQ:TNDM) valued between $1,001 and $15,000 on September 22nd, 2023.
• Tandem Diabetes Care reported a loss of $0.48 earnings per share, missing consensus estimates, while its revenue increased by 8.5% year-over-year to $240.68 million.
• Major recent institutional activities include CWM LLC increasing its stake by 686.2%, highlighting strong investor interest in Tandem Diabetes Care.

Representative Josh Gottheimer (D-New Jersey) recently bought shares of Tandem Diabetes Care, Inc. NASDAQ: TNDM. In a filing disclosed on October 15th, the Representative disclosed that they had bought between $1,001 and $15,000 in Tandem Diabetes Care stock on September 22nd. The trade occurred in the Representative's "MORGAN STANLEY - SELECT UMA ACCOUNT # 1" account.

Representative Josh Gottheimer also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Baldwin Insurance Group NASDAQ: BWIN on 9/23/2025.
• Purchased $1,001 - $15,000 in shares of CommVault Systems NASDAQ: CVLT on 9/23/2025.
• Purchased $1,001 - $15,000 in shares of Sysmex OTCMKTS: SSMXY on 9/22/2025.
• Purchased $1,001 - $15,000 in shares of Independence Realty Trust NYSE: IRT on 9/22/2025.
• Purchased $1,001 - $15,000 in shares of Natera NASDAQ: NTRA on 9/22/2025.
• Sold $1,001 - $15,000 in shares of Diageo NYSE: DEO on 9/22/2025.
• Sold $1,001 - $15,000 in shares of Trade Desk NASDAQ: TTD on 9/11/2025.
• Sold $1,001 - $15,000 in shares of Intuitive Surgical NASDAQ: ISRG on 9/3/2025.
• Purchased $1,001 - $15,000 in shares of Natera NASDAQ: NTRA on 8/22/2025.
• Sold $1,001 - $15,000 in shares of Sysmex OTCMKTS: SSMXY on 8/21/2025.

Tandem Diabetes Care Price Performance

TNDM opened at $15.29 on Friday. The firm has a market cap of $1.03 billion, a P/E ratio of -4.95 and a beta of 1.48. The firm has a 50-day moving average of $12.55 and a 200 day moving average of $16.47. The company has a debt-to-equity ratio of 2.32, a quick ratio of 1.88 and a current ratio of 2.44. Tandem Diabetes Care, Inc. has a fifty-two week low of $9.98 and a fifty-two week high of $38.28.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last released its earnings results on Wednesday, August 6th. The medical device company reported ($0.48) earnings per share for the quarter, missing analysts' consensus estimates of ($0.40) by ($0.08). Tandem Diabetes Care had a negative net margin of 20.51% and a negative return on equity of 65.40%. The company had revenue of $240.68 million for the quarter, compared to the consensus estimate of $238.39 million. During the same period in the prior year, the company earned ($0.47) earnings per share. The firm's revenue was up 8.5% on a year-over-year basis. On average, research analysts expect that Tandem Diabetes Care, Inc. will post -1.68 EPS for the current year.

Wall Street Analysts Forecast Growth

TNDM has been the subject of several research reports. Truist Financial set a $16.00 price objective on Tandem Diabetes Care and gave the company a "hold" rating in a report on Wednesday. Wall Street Zen downgraded Tandem Diabetes Care from a "hold" rating to a "sell" rating in a research note on Saturday, June 21st. Wells Fargo & Company cut their price target on Tandem Diabetes Care from $20.00 to $13.00 and set an "equal weight" rating for the company in a research note on Thursday, August 7th. Royal Bank Of Canada cut their target price on shares of Tandem Diabetes Care from $45.00 to $25.00 and set an "outperform" rating for the company in a research report on Thursday, August 7th. Finally, Canaccord Genuity Group reiterated a "buy" rating and set a $24.00 target price on shares of Tandem Diabetes Care in a research report on Monday, September 29th. Five equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $22.19.

Insider Buying and Selling at Tandem Diabetes Care

In other Tandem Diabetes Care news, CFO Leigh Vosseller acquired 13,720 shares of the company's stock in a transaction that occurred on Friday, August 8th. The stock was bought at an average price of $10.89 per share, with a total value of $149,410.80. Following the completion of the purchase, the chief financial officer owned 25,580 shares of the company's stock, valued at approximately $278,566.20. This represents a 115.68% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO John F. Sheridan acquired 10,000 shares of the company's stock in a transaction that occurred on Monday, August 11th. The shares were acquired at an average cost of $10.23 per share, with a total value of $102,300.00. Following the purchase, the chief executive officer directly owned 106,327 shares of the company's stock, valued at $1,087,725.21. This trade represents a 10.38% increase in their position. The disclosure for this purchase can be found here. 1.90% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. 180 Wealth Advisors LLC bought a new position in Tandem Diabetes Care in the 3rd quarter worth about $126,000. CWM LLC boosted its position in shares of Tandem Diabetes Care by 686.2% in the third quarter. CWM LLC now owns 21,983 shares of the medical device company's stock valued at $267,000 after acquiring an additional 19,187 shares during the period. Inspire Investing LLC boosted its position in shares of Tandem Diabetes Care by 84.3% in the third quarter. Inspire Investing LLC now owns 38,419 shares of the medical device company's stock valued at $466,000 after acquiring an additional 17,576 shares during the period. Voya Investment Management LLC boosted its position in shares of Tandem Diabetes Care by 26.4% in the third quarter. Voya Investment Management LLC now owns 174,146 shares of the medical device company's stock valued at $2,114,000 after acquiring an additional 36,397 shares during the period. Finally, Praxis Investment Management Inc. bought a new position in Tandem Diabetes Care in the 3rd quarter valued at $150,000.

About Representative Gottheimer

Josh Gottheimer (Democratic Party) is a member of the U.S. House, representing New Jersey's 5th Congressional District. He assumed office on January 3, 2017. His current term ends on January 3, 2027. Gottheimer (Democratic Party) is running for re-election to the U.S. House to represent New Jersey's 5th Congressional District. He declared candidacy for the 2026 election. Gottheimer is also running for election for Governor of New Jersey. He declared candidacy for the Democratic primary scheduled on June 10, 2025. Gottheimer attended the University of Pennsylvania for his undergraduate degree. He became a Thouron Fellow at Oxford and attended Harvard Law School. Gottheimer worked as a speech writer under former President Bill Clinton (D), assisting with two State of the Union addresses, among other projects. Before running for Congress, he worked for Microsoft as a general manager for corporate strategy.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.